Transport barriers in transscleral drug delivery for retinal diseases.
about
Dexamethasone intravitreal implant in the treatment of diabetic macular edemaAdvances in drug delivery to the posterior segmentTopical Use of Angiopoietin-like Protein 2 RNAi-loaded Lipid Nanoparticles Suppresses Corneal NeovascularizationPharmaceutical intervention for myopia control.Sonoporation enhances chemotherapeutic efficacy in retinoblastoma cells in vitroOcular drug delivery.Drug delivery to the posterior segment of the eye for pharmacologic therapy.Intrascleral drug delivery to the eye using hollow microneedles.Ocular delivery of pRNA nanoparticles: distribution and clearance after subconjunctival injection.Novel dexamethasone-loaded nanomicelles for the intermediate and posterior segment uveitisNovel Nanomicellar Formulation Approaches for Anterior and Posterior Segment Ocular Drug Delivery.Suprachoroidal drug delivery to the back of the eye using hollow microneedlesOphthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications.Sustained subconjunctival protein delivery using a thermosetting gel delivery system.Ocular distribution, spectrum of activity, and in vivo viral neutralization of a fully humanized anti-herpes simplex virus IgG Fab fragment following topical applicationTechnical brief: subretinal injection and electroporation into adult mouse eyes.Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators.The role of blood-ocular barrier transporters in retinal drug disposition: an overview.Feasibility of lipid nanoparticles for ocular delivery of anti-inflammatory drugs.Topical delivery of antifungal agents.Emerging therapeutic approaches in the management of retinal angiogenesis and edema.Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis.Delivery of intraocular triamcinolone acetonide in the treatment of macular edema.Intravitreal drug delivery in retinal disease: are we out of our depth?Advances in ocular drug delivery: emphasis on the posterior segment.Ocular drug delivery systems: An overview.Cubosomes and other potential ocular drug delivery vehicles for macromolecular therapeutics.Simulating intravitreal injections in anatomically accurate models for rabbit, monkey, and human eyes.In vitro transport and partitioning of AL-4940, active metabolite of angiostatic agent anecortave acetate, in ocular tissues of the posterior segment.In-vitro permeation of bevacizumab through human sclera: effect of iontophoresis application.Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration.Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop.Transscleral passive and iontophoretic transport: theory and analysis.Principles of pharmacology in the eye.Subchoroidal Release of VEGF and bFGF Produces Choroidal Neovascularization in Rabbit.Characterization of liposomal carriers for the trans-scleral transport of Ranibizumab.Extended Duration Vascular Endothelial Growth Factor Inhibition in the Eye: Failures, Successes, and Future Possibilities.Ocular Drug Delivery.Ocular drug delivery targeted by iontophoresis in the suprachoroidal space using a microneedle.Intracameral dexamethasone injection in the treatment of cataract surgery induced inflammation: design, development, and place in therapy
P2860
Q26799423-84B31992-2311-4013-BB57-703CEA0319CBQ26995920-3F89F69B-C6CA-4455-A6D3-977B07E40F27Q28831101-A72FF6C0-9A1D-4528-84C2-9CC66DFD1253Q30472509-42B7DAA5-AD5C-4F6F-B487-D4FD1533C899Q30473275-655AA1FC-653E-466E-B1CC-503AFA9B8127Q30475605-8C34A4AA-FF5C-4EAF-8EFB-08F59A60E015Q30478379-B8D7624C-9DFA-4ECA-AE80-1CAF40AEC294Q33978350-587E58D8-9D09-4A15-8766-0B23447292B8Q34011377-C7E73CA8-BF13-411F-995F-6F998F281030Q34265155-730525B4-ED37-4198-ACB2-F57FE8835049Q34512297-526AB477-DB75-4EBF-9B54-356F75FF4B25Q34572627-0053D896-AC38-4679-9143-AC71D0BDBF2AQ34701929-0B3BEA67-D700-49AF-8DD2-0A9D95E41D47Q34987321-85330E74-49B6-445F-86AC-18B91AB94F3CQ35806468-E5F4156C-8D58-45AA-9B40-9C232CDAA45CQ36995732-E59DE9BA-81B3-4CC4-A3B6-8C0F66F42C42Q37266286-C9463E09-A99E-47A1-8733-A393816721D1Q37741227-2A67CAFB-4691-495E-B95B-EEC04ACADBD9Q37769529-B3EEBCA2-433D-4D9E-ACCB-3226D9DA4486Q37801662-CBFB6A81-2055-4F33-87A5-173BF735D733Q37822290-B6E68BF5-3337-4500-882F-5DAEF77078D2Q37845396-F4728B1C-F302-4596-B4B6-EA730E29902CQ38168356-B663788A-2A7D-4274-8FC0-259A141C9C3BQ38220453-BAEDD68B-E55C-49BB-A98E-790594044B3AQ38224320-F0EBA8A7-2B1C-4F90-80DE-4137B60DBC60Q38318837-1AE96744-9AE0-42EF-B40F-383C773C02E7Q38368715-6B0D65EA-A1AC-47AD-ACA7-E8AF96425A83Q41157546-4F58C0FB-95BD-4C6A-BD10-878C902C7356Q42871357-E1ADFE51-50D0-4272-85C9-B993C30B8AEBQ42925005-75BB9376-D3D9-45F9-968E-79A6C386575CQ43059687-A247C7E7-A172-4D69-A0BD-BB93C5052054Q43245437-0837A289-37EE-4D15-8FD3-AFFFC2930B62Q45305545-7807FE3C-93F6-45F7-B17C-445B8D5ACAA6Q45871474-46763AC8-1DBD-48BE-9EC6-773298F75AADQ46676094-E0D632B6-32C5-45B0-BC5B-6D86E13DF846Q47156996-884F2A24-9143-467E-886E-7BA03DFFB19CQ47704189-A9A103DA-D9DF-4726-AA89-D88D870DFCDCQ51122641-F2537BC4-B41F-4748-B392-4C55F51C215AQ52673868-8E45AD0B-76B6-4931-95C0-F3FE1B59601FQ59125905-CE94EC67-5E77-4969-9F1B-40DA85F616DB
P2860
Transport barriers in transscleral drug delivery for retinal diseases.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Transport barriers in transscleral drug delivery for retinal diseases.
@en
type
label
Transport barriers in transscleral drug delivery for retinal diseases.
@en
prefLabel
Transport barriers in transscleral drug delivery for retinal diseases.
@en
P2093
P2860
P356
P1433
P1476
Transport barriers in transscleral drug delivery for retinal diseases.
@en
P2093
Michael R Robinson
Nam Sun Wang
Robert J Lutz
Stephanie H Kim
P2860
P304
P356
10.1159/000108117
P577
2007-09-12T00:00:00Z